118 related articles for article (PubMed ID: 29976776)
1. Getting to transplant in Hodgkin lymphoma: BVB.
Gordon LI
Blood; 2018 Jul; 132(1):1-3. PubMed ID: 29976776
[No Abstract] [Full Text] [Related]
2. Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients.
Uncu Ulu B; Dal MS; Yönal Hindilerden İ; Akay OM; Mehtap Ö; Büyükkurt N; Hindilerden F; Güneş AK; Yiğenoğlu TN; Başcı S; Kızıl Çakar M; Yanardağ Açık D; Korkmaz S; Ulaş T; Özet G; Ferhanoğlu B; Nalçacı M; Altuntaş F
J Chemother; 2022 May; 34(3):190-198. PubMed ID: 34514960
[TBL] [Abstract][Full Text] [Related]
3. Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.
LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
Br J Haematol; 2020 May; 189(3):e86-e90. PubMed ID: 32048731
[No Abstract] [Full Text] [Related]
4. Salvage regimens for Hodgkin's lymphoma in the brentuximab vedotin era.
Vitolo U; Chiappella A
Lancet Oncol; 2018 Feb; 19(2):162-163. PubMed ID: 29276023
[No Abstract] [Full Text] [Related]
5. Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma.
Forlenza CJ; Gulati N; Mauguen A; Absalon MJ; Castellino SM; Franklin A; Keller FG; Shukla N
Blood Adv; 2021 Dec; 5(24):5519-5524. PubMed ID: 34559223
[TBL] [Abstract][Full Text] [Related]
6. Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience.
Sawas A; Ma H; Kuruvilla J; Lue JK; Deng C; Marchi E; Montanari F; Cheng B; Savage KJ; Villa D; Crump M; Connors JM; O'Connor OA
Leuk Lymphoma; 2020 Dec; 61(12):3014-3017. PubMed ID: 32720828
[No Abstract] [Full Text] [Related]
7. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L
Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977
[No Abstract] [Full Text] [Related]
8. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
Blood; 2018 Jul; 132(1):40-48. PubMed ID: 29703778
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?
Shanbhag S; Prasad V
Eur J Cancer; 2018 Nov; 104():252-253. PubMed ID: 30342911
[No Abstract] [Full Text] [Related]
10. Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation.
El Cheikh J; Massoud R; Haffar B; Fares E; Mahfouz R; Jisr T; Kharfan-Dabaja MA; Mougharbel A; Youssef A; Bazarbachi A; Ibrahim A
Leuk Lymphoma; 2017 Nov; 58(11):2745-2747. PubMed ID: 28351183
[No Abstract] [Full Text] [Related]
11. Comment on "Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.".
Picardi M; Giordano C
Haematologica; 2021 Apr; 106(4):1226-1227. PubMed ID: 33792226
[No Abstract] [Full Text] [Related]
12. Brentuximab vedotin-based salvage treatment in Hodgkin's lymphoma.
Vitolo U; Chiappella A
Lancet Oncol; 2018 Sep; 19(9):1144-1146. PubMed ID: 30122617
[No Abstract] [Full Text] [Related]
13. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
Zinzani PL; Vitolo U; Viviani S; Corradini P; Motta G; Tani M; Cascavilla N; Hohaus S; Merli F; Argnani L; Broccoli A
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):404-8. PubMed ID: 25840816
[TBL] [Abstract][Full Text] [Related]
14. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
15. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
Wagner SM; Melchardt T; Egle A; Magnes T; Skrabs C; Staber P; Simonitsch-Klupp I; Panny M; Lehner B; Greil R; Keil F; Jäger U; Sillaber C
Eur J Haematol; 2020 Mar; 104(3):251-258. PubMed ID: 31838747
[TBL] [Abstract][Full Text] [Related]
16. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
Howell M; Gibb A; Radford J; Linton K
Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404
[No Abstract] [Full Text] [Related]
17. Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.
Kalac M; Lue JK; Lichtenstein E; Turenne I; Rojas C; Amengual JE; Sawas A; Deng C; Mapara MY; Connors JM; Kuruvilla J; O'Connor OA
Br J Haematol; 2018 Mar; 180(5):757-760. PubMed ID: 27984643
[No Abstract] [Full Text] [Related]
18. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
[TBL] [Abstract][Full Text] [Related]
19. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL.
Friedberg JW; Forero-Torres A; Bordoni RE; Cline VJM; Patel Donnelly D; Flynn PJ; Olsen G; Chen R; Fong A; Wang Y; Yasenchak CA
Blood; 2017 Dec; 130(26):2829-2837. PubMed ID: 29038340
[TBL] [Abstract][Full Text] [Related]
20. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.
Chen R; Gopal AK; Smith SE; Ansell SM; Rosenblatt JD; Savage KJ; Connors JM; Engert A; Larsen EK; Huebner D; Fong A; Younes A
Blood; 2016 Sep; 128(12):1562-6. PubMed ID: 27432875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]